Blk Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 419259 trihydrochloride | 1435934-25-0 | sc-361094 | 5 mg | $213.00 | 6 | |
A 419259 trihydrochloride functions as a selective modulator of cellular signaling pathways, exhibiting unique interactions with specific receptors. Its chemical structure promotes effective hydrogen bonding, enhancing affinity for target sites. The compound's stability in aqueous environments allows for sustained activity, while its kinetic profile reveals a rapid engagement with molecular targets, leading to significant alterations in downstream signaling cascades. Additionally, its ionic nature contributes to enhanced solubility, facilitating effective cellular uptake. | ||||||
Lck Inhibitor Inhibitor | 213743-31-8 | sc-204052 | 1 mg | $362.00 | 5 | |
Lck Inhibitor acts as a potent disruptor of protein-protein interactions, specifically targeting the Lck kinase domain. Its unique conformation allows for precise binding to the ATP-binding site, effectively blocking phosphorylation events. The compound exhibits a favorable reaction kinetics profile, characterized by a rapid onset of action and prolonged engagement with its target. Its hydrophilic characteristics enhance solubility, promoting efficient distribution within cellular compartments, thereby influencing various signaling networks. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor primarily targeting BCR-ABL, but can also affect other kinases and potentially influence Blk activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Another broad-spectrum tyrosine kinase inhibitor, which could potentially impact Blk among other kinases. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Primarily targets the epidermal growth factor receptor (EGFR) but may have off-target effects on other tyrosine kinases including Blk. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases and might indirectly affect Blk activity through its broad-spectrum activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
A multi-targeted tyrosine kinase inhibitor that could potentially have an effect on Blk. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
A BCR-ABL inhibitor that may also affect other tyrosine kinases including Blk. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
A potent multi-kinase inhibitor that could potentially impact Blk activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits cyclin-dependent kinases (CDKs) and might indirectly influence Blk through cell cycle regulation pathways. | ||||||